The Relapse-to-Therapy Interval in Relapsed or Refractory Diffuse Large B Cell Lymphoma Is Associated with Clinical Outcomes von Caimi, Paolo F., Auberle, Christine, Goparaju, Krishna, Gallogly, Molly Megan, Baidoun, Firas, Cashen, Amanda F, Hill, Brian T.

Volltext

A Phase I Clinical Trial of Fully Human Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies von Cooper, Brenda W, Gallogly, Molly Megan, Metheny, Leland, Klisovic, Rebecca B., Boughan, Kirsten Marie, Reese Koc, Jane, Wu, Darong, Deng, Changchun, Van Besien, Koen, Tupta, Rose, Schneider, Dina, Ciarrone, Lisa, de Lima, Marcos, Caimi, Paolo F., Tomlinson, Benjamin K.

Volltext

Midostaurin: an emerging treatment for acute myeloid leukemia patients von Gallogly, Molly Megan, Lazarus, Hillard M

Volltext

Kinetics of the Mammalian Glutaredoxins: GRx2 Is Less Active, But Mimics the Catalytic Mechanism of GRx1 von Gallogly, Molly Megan, Starke, David W, Leonberg, Amanda K, Mieyal, John J

Volltext